Xcout IntelSign inSubscribe

YD Bio Limited

YDESBiotechTaipei, Taiwan

Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

Subscribe to see YD Bio Limited’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

YD Bio Limited at a glance

YD Bio Limited is a biotech company headquartered in Taipei, Taiwan. It is publicly listed (YDES) with a market capitalisation of $476.7M. Xcout tracks 8 named people at YD Bio Limited, including Ethan Shen (CEO & Chairman).

Industry
Biotech
Headquarters
Taipei, Taiwan
Market cap
$476.7M
Employees
15
Ticker
YDES

YD Bio Limited leadership

  • Ethan ShenCEO & Chairman
  • Edmund HenChief Financial Officer
  • Benjamin ZhangChief Medical Officer & Director
  • Bo-Xiang ZhangDirector
  • Ethan PhD ShenDirector
  • Jerry Yin-Chia LeeDirector

2 more named people on record for YD Bio Limited, with roles, board committees and tenure — see the full roster →

YD Bio Limited competitors

A few of YD Bio Limited's closest competitors — see the full list of competitors and alternatives →

AXIM BIOTECHNOLOGIES, INC.AXIM · BiotechSan Diego, United States
61% matchPublic

AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.

Market cap$1M
Employees6
AXIM BIOTECHNOLOGIES, INC. competitors & alternatives →

Get YD Bio Limited's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

YD Bio Limited — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on YD Bio Limited in Xcout Intel

  • 8 named people with titles, LinkedIn and board committees
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →